Journal
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
Volume 75, Issue 8, Pages -Publisher
WILEY
DOI: 10.1111/ijcp.14302
Keywords
-
Funding
- Carlos III Health Institute [PI15/00082, PI18/00209, PI15/00013, SAF2014-57845-R]
- Spanish Ministry of Health
- Spanish Ministry of Economy and Competiveness
- European Regional Development Fund
- Conselleria de educacion, investigacion, cultura valenciana, Generalitat valenciana [AICO2019/250]
- Ministerio de Educacion y Ciencia (Universitat de Valencia Estudi General curso 2013/2014)
- Instituto de Salud Carlos III [JR18/00051]
- European Regional Development Fund (FEDER) [JR18/00051]
- Instituto de Salud Carlos III of Madrid [CM19/00027]
Ask authors/readers for more resources
This pilot study found significantly higher levels of CXCL10 in T2D patients with DPN compared to those without DPN, suggesting a potential role of this chemokine in the development of DPN. Determination of CXCL10 levels could serve as a marker for early detection and implementation of therapeutic strategies to reverse and prevent DPN.
Background Diabetic peripheral neuropathy (DPN) is a chronic complication of diabetes mellitus associated with high morbidity and mortality. Major risk factors for DPN include metabolic changes, duration of diabetes, nerve ischaemia and derangements in regeneration and nerve repair programmes. Chemokines have been previously implicated in the pathogenesis of various neuropathies and neuropathic pain processes. The aim of this pilot study was to evaluate the association between the plasma levels of chemokines (CXCL9, CXCL10 and CXCL11) in the presence of DPN in a cohort of type 2 diabetes (T2D) patients. Materials and methods We studied 73 patients with T2D: 36 with DPN and 37 without DPN. DPN was established through the Semmes-Weinstein test (SW). Plasma levels of circulating chemokines CXCL9, CXCL10 and CXCL11 were determined using DuoSet ELISA kits (Abingdon, UK). Results We found that levels of CXCL10 were significantly higher in patients with DPN than amongst patients without DPN (57.6 +/- 38.3 vs 38.1 +/- 33.4 pg/mL, respectively; P = .034). Serum levels of chemokine CXCL9 were also higher amongst patients with DPN but did not reach a statistical significance (188.1 +/- 72.7 and 150.4 +/- 83.6 pg/mL, respectively, P = .06). Conclusions Increased circulating levels of CXCL10 were associated with DPN in T2D patients, suggesting a role of this chemokine in the DPN. Determination of CXCL10 levels could be used as a marker for the early detection and implementation of therapeutic strategies in order to reverse and prevent the DPN.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available